Toleranzia AB
0EH
Company Profile
Business description
Toleranzia AB is a Swedish biotechnology company. It develops drugs that harness the power of the immune system to treat autoimmune orphan diseases. The company uses its tolerance technology for drug development, which is based on the identification of disease-specific proteins that are developed into biological drugs, specific to each autoimmune disease. Its drug development pipeline includes TOL2, which is being developed for the treatment of autoimmune orphan disease myasthenia gravis, and TOL3, being developed for another indication in autoimmune orphan diseases, ANCA vasculitis.
Contact
Arvid Wallgrens backe 20
8th floor
Gothenburg413 46
SWET: +46 763199898
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
10
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,828.70 | 2.30 | 0.03% |
| CAC 40 | 7,766.71 | 43.24 | 0.56% |
| DAX 40 | 24,206.91 | 133.24 | 0.55% |
| Dow JONES (US) | 44,240.76 | 165.60 | -0.37% |
| FTSE 100 | 8,854.18 | 47.65 | 0.54% |
| HKSE | 24,148.07 | 260.24 | 1.09% |
| NASDAQ | 20,418.46 | 5.95 | 0.03% |
| Nikkei 225 | 39,688.81 | 101.13 | 0.26% |
| NZX 50 Index | 12,839.69 | 19.33 | -0.15% |
| S&P 500 | 6,225.52 | 4.46 | -0.07% |
| S&P/ASX 200 | 8,590.70 | 1.40 | 0.02% |
| SSE Composite Index | 3,497.48 | 24.35 | 0.70% |